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ABSTRACT 
 Since its introduction less than four years ago, noninvasive prenatal screening (NIPS) 
has been widely adopted as a screening tool for women at a high-risk for fetal aneuploidy.  
As use expands into the general population, questions arise concerning the integration of 
NIPS into preexisting screening routines.  We surveyed 208 practicing genetic counselors to 
assess the current use of NIPS.  Genetic counselors were queried as to the 
advantages/disadvantages of offering NIPS to all patients regardless of a priori risk.  Results 
indicate substantial variation in practice.  The majority of participants report offering NIPS in 
conjunction with another method of screening for fetal aneuploidy, indicating that NIPS is 
being used as an addition rather than as a replacement.  Most offer NIPS with another form 
of screening, predominantly either first trimester ultrasound, NT, and an MSAFP (45.1%, 
n=78), or first trimester serum screening, with or without an NT, and an MSAFP (19.7%, 
n=34).  Counselors are evenly split on the merits of expanding the use of NIPS to the general 
population (con: 55.3%, n=105; pro: 44.7%, n=85).  The lack of consensus among 
respondents suggests that practice guidelines might benefit counselors at this time.  In 
addition, the respondents emphasize the significance of better educating providers about the 
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INTRODUCTION 
 The introduction of noninvasive prenatal screening (NIPS) technology has generated 
considerable interest, as it promises to be a screen with higher detection rates and lower false 
positive rates than preexisting screening methods, minimal physical risk to mother and fetus, 
and information on multiple chromosomal conditions.  As centers across the country increase 
their use of this new technology, it is important to carefully consider the benefits, risks, and 
limitations of NIPS relative to alternative screening tests to determine how best to integrate 
this tool into the existing machinery of prenatal screening.     
 




 In December 2012, the American Congress of Obstetricians and Gynecologists 
(ACOG) and the Society of Maternal-Fetal Medicine (SMFM) approved the use of NIPS in 
high-risk women.  This joint committee opinion did not endorse the use of NIPS in women at 
a low-risk for fetal aneuploidy due to a lack of adequate performance studies (ACOG, 2012).  
The American College of Medical Genetics and Genomics (ACMG) took a similar stance in 
a policy statement published in February 2013 (Gregg et al., 2013), emphasizing that NIPS 
should not replace a first trimester ultrasound or invasive testing.  In addition, the authors 
underscored that this technology is a screen and not a diagnostic test.  A National Society of 
Genetic Counselors (NSGC) position paper, published in January 2013 reminded providers 
that this screening should not be considered first-tier testing and highlighted the importance 
of pre and post-test counseling (Devers et al., 2013).  As of now, these position statements 
have not been revised, and currently none of the major organizations support the use of NIPS 
in the low-risk population. 
Sensitivity and specificity of noninvasive prenatal screening technology in the general 
population 
 Four main companies pioneered the clinical use of NIPS, using cell-free DNA 
(cfDNA) to assess a pregnancy’s risk for certain aneuploidies and other chromosomal 
abnormalities.  These four companies are Sequenom, Verinata (since purchased by Illumina), 
Ariosa Diagnostics, and Natera.  Recently, more laboratories have announced that they will 
offer their own version of NIPS, indicating that the testing may soon become less specialized.  
The four primary companies all use different methods and the screens vary in terms of what 
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chromosome abnormalities are covered.  For some of the tests, patients must choose to opt in 
for studies of sex chromosomes and/or microdeletions/microduplications. Each company 
uses its own methodology for NIPS, and their benefits and limitations vary, though all 
methods have demonstrated sensitivity and specificity for the identification of Down 
syndrome superior to that of traditional fetal screening.  
 There have been several major studies to evaluate the efficacy of NIPS (Bianchi et al., 
2014; Chetty, Garabedian, & Norton, 2013; Dar et al., 2014; Gil, Quezada, Bregnant, 
Ferraro, & Nicolaides, 2013; Nicolaides, Syngelaki, Ashoor, Birdir, & Touzet, 2012; Norton 
et al., 2012; Norton, Rose, & Benn, 2013; Pergament et al., 2014).  Three studies that focused 
on the use of NIPS in the general population or low-risk population (Bianchi et al., 2014; 
Nicolaides et al., 2012; Pergament et al., 2014) found that NIPS had comparable sensitivities 
and specificities in high and low-risk patients.  
 Nicolaides et al. (2012) and Bianchi et al. (2014) used NIPS technology with a 
sequencing approach in a population with both low and high-risk patients.  Their goal was to 
see if screening would have the same results in this blended population as had been reported 
in high-risk populations.  Pergament et al. (2014) employed NIPS with a single-nucleotide 
polymorphism (SNP) approach, which proved to have several advantages. In this study, the 
authors separated the results by low-risk and high-risk, and then considered them as a whole. 
All three studies, despite differences in methodology, concluded that NIPS’s performance is 
conserved in the low-risk population.  
The Nicolaides et al. (2012) cohort study consisted of 2049 women with a singleton 
pregnancy presenting for first trimester screening (FTS).  These women had both FTS and 
NIPS, allowing the authors to evaluate their relative merits.  Trisomy risk scores were given 
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for 95.1% (1949 of 2049) of affected cases including all eight fetuses with trisomy 21 and 
two of the three fetuses with trisomy 18 (Nicolaides et al., 2012, p. 374.e2).  In addition, 
99.9% (1937 out of 1939) of euploid cases were labeled as having a <1% risk for trisomy 21 
and trisomy 18.  NIPS identified trisomies 21 and 18 with a false positive rate of 0.1% 
(Nicolaides et al., 2012, p. 374.e2).  However, one of the cases of trisomy 18 failed to 
generate a result.  While this does not match the accuracy of diagnostic testing, it did 
demonstrate a higher detection rate and lower false positive rate than traditional FTS. 
There were some limitations to this study.  First, the median maternal weight was 144 
pounds, 22 pounds less than the average weight of an American woman.  Median maternal 
weight would be expected to be higher in many patient populations in the United States 
(Body Measurements, 2012), and higher weight is a major risk factor for low fetal fraction 
and resulting NIPS failure.  Second, for phenotypically normal babies, no cytogenetic testing 
was done to confirm NIPS results.  While it is unlikely that these babies would have trisomy 
21 or trisomy 18, they may have had other cytogenetic findings that would have been 
apparent on a karyotype and/or microarray.  Furthermore, the study included seven 
pregnancies with known abnormal karyotypes that would not be picked up on NIPS.  It is 
possible this number would have been higher if cytogenetic testing had been done on all 
newborns. Third, the 2049 women include 100 women who received no result from NIPS.  
These test failures were either due to low fetal fraction (46 cases) or assay failure (54 cases).  
The 46 cases of low fetal fraction are significant and will also be considered in the context of 
the findings from Pergament et al. (2014), which are discussed below.  The n of 2049 does 
not include an additional 100 women for whom NIPS could not be run because of laboratory 
error (70 cases), inadequate sample volume (29 cases), or incorrect labeling (1 case).  In 
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total, there were 200 women who did not have NIPS results.  The authors conclude that the 
detection rate of trisomies is a function of assay precision and fetal fraction, not prevalence, 
suggesting that the population being tested would not have an effect on the accuracy of the 
testing.   
Bianchi et al. (2014) was based on the CARE (Comparison of Aneuploidy Risk 
Evaluations) study, a prospective, blinded, multicenter study to analyze the performance of 
NIPS in comparison to traditional screening.  The study enrolled 2042 women that had either 
already had or planned to have FTS or a second trimester maternal serum screen (quad). 
Eighteen women, (0.9%) did not get a result because of problems during extraction or 
sequencing.  Of note, 28.5% of the total had NIPS in the third trimester, which represents a 
drastic deviation from how this screening would typically be used in practice.   
In the CARE study, NIPS performed equally well in a general population as it has in 
the high-risk population, and outperformed standard screening.  NIPS had lower false 
positive rates for trisomy 21 and trisomy 18 than FTS.  For trisomy 21, there were six false 
positives (0.3%) with NIPS compared to sixty-nine (3.6%) with traditional screening 
(Bianchi et al., 2014, p. 803).  For trisomy 18, three patients (0.2%) had a false positive with 
NIPS while eleven (0.6%) had a false positive with traditional screening (Bianchi et al., p. 
803).  Of all patients with false positives, none had a false positive on both screens, and both 
screens detected all eight cases of aneuploidy (five trisomy 21, two trisomy 18, and one 
trisomy 13.  Again, for the false positives, assessment at birth included normal physical 
exams, but no cytogenetic testing, and confined placental mosaicism or maternal mosaicism 
cannot be ruled out (Bianchi et al., 2014, 806).  
 Out of the 1,051 women in the study by Pergament et al (2014), 533 (50.7%) were  
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considered high-risk and 518 (49.3%) were considered low-risk. Participants were not 
provided with their NIPS results.  NIPS results included risk assessments for trisomy 21, 
trisomy 18, trisomy 13, and monosomy X (Turner syndrome).  In addition, all NIPS results 
were confirmed with cytogenetic testing, closing another gap from previous studies. 
 Of the women studied, 966 (91.9%) of the NIPS returned a result.  The overall 
sensitivity (trisomy 21, trisomy 18, trisomy 13, and monosomy X) was 98.1% and the overall 
specificity was 99.8%.  Again, results suggest that the sensitivity and specificity do not suffer 
in the low-risk population (Pergament et al., 2014, p. 6).  A significant difference between 
the two populations was that NIPS more frequently failed to produce a result in the low-risk 
population.  The authors attribute this to an earlier gestational age at the time of the blood 
draw in the low-risk population, which increases the chances of low fetal fraction.   
When looking at the samples from both populations combined, the authors found that 
16% (20/125) of the true aneuploidy samples did not produce a result (Pergament et al., 
2014, p. 2).  Fifteen of these samples (75%) had low fetal fraction or low fetal fraction and 
insufficient data clarity, and ten had a fetal fraction below 3.4%, which is considered to be 
below the 1.5th percentile (Pergament et al., 2014, p. 5).  From this, the authors conclude that 
samples with less than 3.4% fetal fraction were six times more likely to be abnormal than the 
samples with a fetal fraction greater than 3.4%, highlighting the importance of following-up 
with patients for whom NIPS failed to provide a result.    
Despite increased problems with fetal fraction, NIPS maintains a high sensitivity and 
specificity in the low-risk population.  However, there are issues concerning the positive 
predictive value (PPV) of the test.  Many studies do not consider PPV and, notably, PPV is 
often missing from the materials produced by the laboratories.  In a lecture about the 
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marketing of NIPS, Stoll (2014a) detailed her analysis of published PPV values, and focused 
on one particular laboratory whose values were accessible.  She used their quoted sensitivity, 
specificity, and PPV, to determine the incidence of Down syndrome, essentially working 
backwards.  She found that the incidence had to be 1 in 4 in order for the values to be true.  
While the laboratory does not disclose the incidence of Down syndrome from their “internal 
data,” Stoll was critical of high PPV rates reported by this laboratory, explaining that based 
on the accessible values, her independent calculation of PPV was much lower.  
Several others have noted the failure to discuss, and the importance, of PPV 
(Begleiter & Finley, 2014; Mennuti, Cherry, Morrissette, & Dugoff, 2013; Mennuti, Cherry, 
Morrissette, & Dugoff, 2014; Stoll & Lindh, 2015).  Begleiter and Finley (2014) highlight 
the difference in PPV and sensitivity and specificity.  They calculated the PPV, for each of 
the four major commercial versions of NIPS, for a 35-year-old woman with no other risk 
factors whose screen is positive for Down syndrome.  The PPVs ranged from >28% to >80%.  
These two companies with the lowest and highest calculated PPVs, both claim specificities 
and sensitivities of at least 99%.  In this exercise, they emphasize that false positives are a 
very real possibility.  In a reply to Begleiter and Finley’s letter to the editor, Mennuti et al. 
(2014) state that obstetricians must keep in mind that as NIPS is increasingly used for low-
risk women and as other, rarer, conditions are added to the screen, the PPV will drop.   
Utility of first trimester screening (FTS) and maternal serum screening in comparison 
to NIPS 
 Use of NIPS has grown and continues to grow very rapidly, accompanying and in 
some cases replacing the use of other prenatal screening modalities.  In comparing NIPS to 
FTS and maternal serum screening, the primary measure is the relative sensitivity and 
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specificity of each method.  However, there are ancillary benefits of FTS and maternal serum 
screening worth consideration.  
 The argument has been made that if NIPS becomes the standard screen, there will be 
no reason to continue taking nuchal translucency measurements (NT) since NT detects only 
aneuploidy and has not been proven to be clinically useful for detecting fetal heart defects or 
other anomalies (Shulman, 2014). However, some studies suggest that NT has other utility, 
and that the first trimester ultrasound screens for more than aneuploidy.  
In a comprehensive review, Nicolaides searched PubMed to gather over a decade’s 
worth of studies and articles looking at the utility of nuchal translucency and other first 
trimester ultrasound findings as screening for chromosome abnormalities (Nicolaides, 2004).  
Nicolaides concluded that increased NT can be associated with a variety of conditions, 
including, trisomy 21, Turner syndrome, other chromosome abnormalities, fetal 
malformations, and genetic syndromes.  The cause of the enlarged NT can be cardiac defects, 
venous congestion, diaphragmatic hernias, skeletal dysplasias, problems with the 
development of the lymphatic system, and more.   These causes may be isolated or 
syndromic.  For example, the fetus could have an isolated heart defect or could have a heart 
defect as a result of having Down syndrome (Nicolaides, Heath, & Cicero, 2002).  From the 
combined data, Nicolaides found that, “the risk of an adverse outcome, which includes 
chromosomal and other abnormalities and fetal and postnatal death, increases with NT 
thickness from approximately 5% for NT between the 95th percentile and 3.4 mm to 30% for 
NT between 3.5 mm and 4.4 mm to 50% for NT of 4.5 to 5.4 mm and 80% for NT of ≥ 5.5 
mm”  (Nicolaides, 2004, p. 47).  While this increased risk does include aneuploidies for 
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which NIPS is highly sensitive, it demonstrates that increased NT can be a significant 
indicator of other fetal anomalies.   
 In addition, Nicolaides pointed to the advantages of an early ultrasound.  Many major 
fetal abnormalities, can be diagnosed at this time, for example, anencephaly, heart defects, 
and abdominal wall defects.  Identifying at risk fetuses earlier provides more time for further 
testing, decision-making, and the option of earlier termination. 
There are two important advantages to FTS that, currently, NIPS cannot replace.  
One, the use of NIPS has not yet been validated in higher level multiple gestations.  Two, an 
NT is almost instantaneous and, depending on the laboratory, the serum results of an FTS can 
be returned within days.  The turnaround time for NIPS is 7-14 days, depending on the 
laboratory.  In the prenatal setting, this difference in timing can be of great importance to the 
patient.  
Another point to consider is the utility of the analyte analysis from maternal serum 
screening.  Certain analytes levels have been linked with poor obstetrical outcomes, 
including intrauterine growth restriction, small for gestational age, spontaneous abortion, and 
preterm birth (Dugoff, 2010; Gagnon et al., 2008; Suskin Kaplan, Neto, Dar, Dolan, & 
Klugman, 2013).  Currently, this information cannot be obtained from NIPS.  Despite the 
correlation between abnormal serum markers and poor obstetrical outcomes, there have not 
been any randomized trials to evaluate the efficacy of interventions (Norton et al., 2014).  
Thus, it is unclear if there is a true benefit, other than knowledge, to identifying these women 
who are at an increased risk for complications. 
 In addition to the merits of existing screening techniques, it is important to consider 
the limitations of NIPS.  A study from Mary Norton, Robert Currier, and Laura Jelliffe-
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Pawlowski (2014), aimed to compare the number of chromosome abnormalities that would 
be found by traditional prenatal screens and NIPS.  They found that out of the screen positive 
women who had an abnormal invasive testing result (n = 2,993), 16.8% (n=504) had fetal 
abnormalities that would not be expected to be picked up by NIPS (Norton et al., 2014).  In 
addition, there is also the issue of test failure, necessitating redraws.  As demonstrated by the 
Pergament et al. (2014) study, failures are particularly troubling as these pregnancies may be 
at higher risk.   
 In addition, it is very possible that some clinicians may not be willing to forego the 
information that can be obtained from existing prenatal screening that is not included in 
NIPS.  Therefore the cost of screening may be based on having combinations of these 
screens, rather than one or the other.  
Purpose of the study 
 Over the past few years, centers across the world have started using cell-free DNA for 
noninvasive prenatal screening (NIPS).  It remains unclear how this technology, will be 
integrated into existing prenatal screening routines.  To date, professional guidelines have not 
supported utilizing NIPS universally, however, many centers across the country have already 
started offering NIPS to low-risk women.  This paper aims to examine the use of NIPS in 
current practice, predominantly in the United States and Canada, in order to inform strategies 
for the optimal use of both new and existing screening techniques. 




 Genetic counselors seeing at least one prenatal patient per week were eligible to 
participate.   
Instrumentation 
 The survey consisted of multiple choice and free-response questions that focused on 
the participant’s current use of noninvasive prenatal screening and his or her thoughts 
regarding how the screening should be used in the near future.  The maximum number of 
questions a participant could answer was twenty-three.  It was initially piloted on a group of 
six genetic counselors who were not otherwise affiliated with the study.  The feedback from 
the pilot was used to improve the language for questions and response choices and ensure 
that the questions asked had the greatest potential to answer the research questions.  The 
survey was administered through SurveyMonkey.  No IP addresses were collected and 
participants were not asked any identifying questions.  Participants were able to return to 
previous questions to change their answers and no questions were mandatory.  
Procedures 
 The Julia Dyckman Andrus Institutional Review Board approved the study on 
December 17, 2014.  An invitation to participate in the study was distributed through the 
Student Research Survey Program to the NSGC distribution list on January 13, 2015  
(N=3,200).  The e-mail briefly described the objectives of the research project and included 
the link for the survey and contact information for the primary investigators.  Recipients were 
welcome to forward the survey to other counselors.  Upon following the link, the participants 
were directed to the informed consent.  A second e-mail sent out to the distribution list on 
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January 20, 2015 as a reminder.  The survey was open until January 27, 2015.  
Data Analysis 
 A total of 208 submissions were received (n = 208).  Two respondents who reported 
seeing less than one patient a week were excluded from the survey (n = 206).  Data analysis 
was performed using SurveyMonkey, Microsoft Excel, and SPSS.  The qualitative questions 
were analyzed by common theme.  This was first done by the research team and then by a 
second coder who was otherwise uninvolved with the study.  The inter-rater reliability was 
calculated for each theme and ranged from 96.7% to 100%, with a mean of 99% (Freelon, 
2013).




 Respondents answered questions regarding where they practice and their typical 
prenatal patient load.  The responses to select demographic questions can be found in Table I. 
Current Practice 
 Participants considered their institution’s current use of NIPS.  These questions 
focused on to whom NIPS is offered and how it is used in relation to other forms of prenatal 
screening.  These responses are represented in Figure 1 and Table II. 
Universal screening 
 Respondents reflected on their feelings regarding the implementation of universal 
NIPS (i.e. offering NIPS to patients both at high and low-risk for fetal aneuploidy).  These 
responses are recorded in Table III.  For qualitative questions, themes that appeared in five or 
more responses are represented in the table. 
NIPS + FTS = ? 
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Table I: Respondent demographic information 
 N = 204 
Variable n % 
Average number of 
prenatal patients seen in 
a week 
10−14 61 29.9 
15−19 52 25.5 
5−9 44 21.6 
 20 or more 27 13.2 
 1-4 20 9.8 
    
Type of institution University medical center 81 39.7 
 Private hospital / medical facility 44 21.6 
 Public hospital / medical facility 38 18.6 
 Physician’s private practice 30 14.7 
 Community hospital 8 3.9 
 Other 3 1.5 
    
Country of practice United States 194 94.6 
 Canada 9 4.4 
 Australia 2 1.0 
    
Region of the United 
States 
East North Central 33 17.2 
Pacific 32 16.7 
 Mid-Atlantic 31 16.2 
 South Atlantic 28 14.6 
 New England 20 10.4 
 Mountain 16 8.3 
 West South Central 14 7.3 
 West North Central 12 6.3 
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Figure 1: Approximately how many of the patients who get NIPS at your center/institution, 
are seen by genetics? 
 
 
Table II: Current practice 
To whom does your center / practice currently offer NIPS? Please check all 
that apply. 
N = 201 
n % 
Patients who are high-risk for aneuploidy (35 years or older at time of 
delivery, positive screen, ultrasound finding, family history) 
190 94.5 
Low-risk patients who request NIPS 76 37.8 
Low-risk patients who present too late for other screening methods or for 
some reason cannot have other screening 
45 22.4 
All patients who present for prenatal care 22 11.0 
Other 12 5.97 
It is not offered to any patient 1 0.5 
   
At your center / practice, how is NIPS typically offered? Please choose the 
answer that reflects how it is most commonly used. 
N = 196 
n % 
In conjunction with a first trimester ultrasound and NT (no first trimester 
serum screening), and an MSAFP 
78 45.1 
In conjunction with first trimester screening (NT and serum screening, or 
serum only), and an MSAFP 
34 19.7 
Instead of first and/or second trimester screening 34 19.7 
In conjunction with sequential screening or integrated screening 13 7.5 
In conjunction with an MSAFP 12 6.9 
In conjunction with second trimester serum screening 2 1.2 
None 
1% 
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Which of the following abnormal values would you discuss further with the 
patient and/or provider, if the patient’s first or second trimester screening 




N = 194 
n % 
Increased NT 182 93.8 
Elevated or decreased AFP 139 71.7 
Elevated or decreased uE3 127 65.5 
Elevated or decreased PAPP-A 126 65.0 
Elevated or decreased hCG 86 44.3 
Elevated or decreased inhibin 62 32.0 
None 5 2.6 
 
Table III: Counselors’ views on the implementation of universal NIPS 
 Do you believe that NIPS should be offered universally (i.e. to any  
pregnant woman, regardless of a priori risk)? 
N = 190 
n % 





Comments on the universal use of NIPS, by theme: 
N = 169 
n % 
Need for more studies / lack of validation in low-risk patients 61 36.1 
NIPS is a better than other available screens 56 33.1 
The importance of patient education / informed consent 36 21.3 
Insurance and cost issues 32 18.9 
Lower test performance in low-risk patients 27 16.0 
The need for provider education / lack of provider understanding 24 14.2 
Concern over NIPS being offered outside of genetics / not enough gc’s 15 8.9 
Against practice guidelines / no guidelines for implementation 13 7.7 
Lack of patient understanding 10 5.9 
Concern over loss of information from other screens 7 4.1 
Fairness / patient autonomy 7 4.1 
Successful validation studies 7 4.1 
Availability of other good screens  5 3.0 
   
 If NIPS is approved for universal use, how do you think it should be 
implemented? 
N = 189 
n % 
In conjunction with a first trimester ultrasound and NT (no first trimester 
serum screening), and an MSAFP 
111 58.7 
In conjunction with an MSAFP 24 12.7 
In conjunction with first trimester screening (NT and serum screening, or 
serum only), and an MSAFP 
20 10.6 
Other 17 9.0 
Instead of first and/or second trimester screening 9 4.8 
In conjunction with sequential screening or integrated screening 6 3.2 
In conjunction with second trimester serum screening 2 1.1 
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Which of the following, if any, would you be concerned about losing in a 
transition to NIPS (assuming NIPS was done with MSAFP)?  Please choose 
all that apply. 
 
N = 192 
n % 
NT 164 85.4 
PAPP-A 58 30.2 
uE3 42 21.9 
hCG 31 16.2 
None 24 12.5 
Inhibin 16 8.3 
   
 In pregnancies with no indications / known risk factors (other than general 
population risk), do you think there should be a gestational age limit for 
NIPS? 
N = 188 
n % 
No 156 83.0 
Yes 32 17.0 
   
Comments on the incorporation of NIPS into prenatal screening routines, by 
theme: 
N = 60 
n % 
The importance of patient education / informed consent 21 35.0 
The need for provider education / lack of provider understanding 21 35.0 
Concern over loss of information from other screens 19 31.7 
Insurance and cost issues / impact on institutional finances 14 23.3 
Concern over NIPS being offered outside of genetics / not enough genetic 
counselors 
11 18.3 
Lab transparency / sales representatives as educators 7 11.7 
Need for investigation into analytes / no proof pregnancy outcome is 
improved 
6 10.0 
Lack of patient understanding 5 8.3 
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DISCUSSION 
Current use  
 Almost all respondents (94%, n=190) report that NIPS is routinely offered to women 
at higher risk for aneuploidy (35 years or older at delivery, positive screen, ultrasound 
finding, family history).  Only one respondent (0.5%) said that NIPS is not offered currently 
offered to any patients. 
 The majority of respondents report using NIPS in conjunction with another form of 
screening in the first trimester.  It is frequently offered in conjunction with a first trimester 
ultrasound, NT, and an MSAFP (45.1%, n=78), or in conjunction with first trimester serum 
screening, with or without an NT, and an MSAFP (19.7%, n=34).  A small number of 
counselors report that it is offered with another form of serum screening alone: 7.5% (n=13) 
sequential or integrated screening, and 1.2% (n=2) for second trimester serum screening.  
Only 19.7% (n=34) of participants responded that it is typically performed instead of first or 
second trimester screening.  Responses suggest that in the majority of cases, NIPS is not 
replacing other screens, but being used in addition. 
 Current practice is extremely varied, both in terms of what combination of testing is 
offered and to whom it is offered.  While there is consensus around offering NIPS to all high-
risk women, there are differences in practice when it comes to the general population.  A 
substantial minority will use NIPS for low-risk patients at the patient’s request (37.8%, 
n=76).  Others offer NIPS to low-risk patients who present too late for other screening 
methods or for some reason cannot have other screening (22.4%, n=45), and 11.0% (n=22) 
offer it to all patients who present for prenatal care.   
 




NIPS in the general population 
 Currently, centers rarely offer NIPS to all obstetrical patients, thus the extensive use 
of NIPS in the general population would seem to be a major shift in practice.  Respondents 
were evenly split on the issue of whether or not NIPS should be offered to all women, with 
44.7% (n=85) in favor of universal access.  In comments, the predominant theme cited in 
support of universal NIPS was that NIPS is better than other available screens (33.1%, n=56).  
Counselors touched on the issue of fairness (4.1%, n=7): “Everyone should be offered the 
best available screen with the highest detection rate and lowest false positive rate.”  Some 
respondents also mentioned the existence of successful validation studies (4.1%, n=7): “A 
number of studies have shown that the efficacy of NIPS for common aneuploidy (PPV, False 
positive rate etc.) is superior to other available screening tests in both high and low risk 
populations.”  In addition, one response served as a reminder that ‘traditional’ screening 
programs have not been around forever: “Screening tests are continually evolving so it is a 
logical next step to move on to the best test.”  
 Among the arguments against universal NIPS, concerns over the lack of validation 
were the most widespread (36.1%, n=61).  One counselor responded: “We do not have 
validation studies in a low risk population.  Without that data, I don't think we can have a 
meaningful discussion of results with a patient. I can't give them any data on the possibility 
false-positive or false-negative because the test hasn't been validated for their use.”  
 Respondents in favor and against universal NIPS wrote about education, with 21.3% 
(n=36) offering comments focused on the importance of patient education and proper 
informed consent: “…I would also hope NIPS is explained well to a patient. At our center, a 
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genetic counselor is almost always involved if NIPS is ordered so those patients get good 
information.”  The lack of provider understanding and the need for provider education 
(14.2%, n=24), along with the lack of patient understanding (5.9%, n=10) were frequently 
used arguments against universal NIPS: “Despite multiple education outreach efforts I'm still 
getting referrals from outside offices with either confused providers or confused patients (i.e. 
‘I was told I could come see you guys first before scheduling my termination or just go ahead 
and schedule the termination’).  So until that is a little more under control I hesitate to say 
everyone should do it.”   
 These concerns were revisited when participants were prompted to share comments 
on the incorporation of NIPS into prenatal screening routines in general.  In response, 35.0% 
(n=21) wrote about the importance of patient education, 35.0% (n=21) wrote about the 
importance of provider education and/or expressed concern over a lack of provider 
understanding, and 8.3% (n=5) expressed concern over a lack of patient understanding.  For 
example, one respondent said, “Every time we have a false positive or false negative they 
[referring obstetricians] are floored.  No matter how many times we reiterate that it is a 
screening test, they don't hear the message.”   
Involvement of genetics professionals 
 Many participants made a case against non-genetics providers offering NIPS.  This 
was raised by 8.3% (n=14) in response to the question of whether or not NIPS should be 
offered universally, and 18.3% (n=11) included it in their final comments.  For example, 
“Non-genetic providers (OB/GYNs, MFMs) who order the test, in my experience, DO NOT 
understand the accuracy of the test/the meaning of an abnormal result.  If they understood 
and were willing to properly counsel their patient regarding the results I would be fine 
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offering it universally. But when the provider says "But the test is 99%" and the actual PPV 
is 10%, I have a problem.”   
 Although counselors may make a case that use of NIPS in the general population, 
where PPV is lower, calls for more rather than less participation by genetic professionals, 
logistical hurdles suggest that expanded use will have the opposite effect.  In this study, just 
under half (45.4%, n=89) of all respondents report that all women who get NIPS are seen by 
genetics, and 50% (n=98) report that more than 25% are seen by genetics.  Assuming no 
radical change in the availability of genetic services, it would be hard to sustain these 
numbers if the use of NIPS was expanded.  As one respondent noted, “Offering NIPS 
involves a great deal of upfront counseling to properly inform the patient of the potential 
results.  Our system is not currently equipped to handle this amount of patient volume.  There 
are not enough genetic counselors/ trained health care workers to handle the demand.”  
Information from other screens 
 Counselors were very varied in their responses regarding concerns over what would 
be lost if NIPS was performed without other screens.  The majority report that they would be 
concerned about losing the value of an NT in a complete transition to NIPS (85.4%, n=164).  
Most counselors report that they currently routinely discuss any abnormal NT or MSAFP 
(93.8%, n=186; 71.7%, n=139), suggesting that losing these sources of information would 
negatively impact clinical practice.  A smaller number of respondents expressed concern 
about losing other analyte values.  Of these, PAPP-A was highest at 30.2% (n=58).  One 
respondent underscored something else that would be lost: “I also feel that we are losing 
something important by not having a risk number - when I see a first trimester result that is 
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abnormal, especially if highly so, I consider and counsel the patient about the possibility of 
genetic conditions other than the condition tested (like Down syndrome).”   
Cost and insurance  
 Because evidence here suggests that NIPS would be an additional screen rather than a 
replacement screen, it raises more concerns about cost and insurance coverage.  A substantial 
number of respondents expressed these concerns when commenting on the implementation of 
universal NIPS (18.9%, n=32).  Specific points of concern included insurance coverage for 
multiple screens, the cost to the patients, the financial impact on the department, and the cost 
to the overall system.  One respondent wrote, “There are very good screens already available 
for this population at a much lower cost.   If NIPS becomes cheaper than other serum 
screening this may be appropriate to offer.  Population screening needs to be as cost effective 
as possible.”  Similar anxieties also emerged in the final comments, where 23.3% (n=14) 
expressed concern about cost and/or reimbursement, such as this: “I think it is a great test, 
but there needs to be a discussion about expense and who is paying. We don't need to be 
doing a $2,000 test on a low risk person when a $160 test will do.”  Investigations into the 
cost effectiveness of testing as well as practice guidelines will likely have a strong impact on 
insurance coverage and thus the cost to the patients.  
Study limitations 
 The survey was distributed through the National Society of Genetic Counselors 
(NSGC) distribution list, which includes only members of NSGC.  The experiences and 
opinions of non-members could not be incorporated into this study.  In addition, the “open 
rate” for the first email was 27.7% and 24.9% for the reminder email.  As with any study, 
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those who are interested in and have strong feelings on the subject are the ones most likely to 
respond. 
Looking forward 
 Based on this data, there is no consensus among genetic counselors on the best use of 
NIPS in high-risk or general populations.  There is large variability in both current practice 
and opinions on what should be done going forward.  However, the responses suggest that at 
least when initially implemented, universal NIPS should be offered in conjunction with some 
form of first trimester screening and an MSAFP.  Counselors expressed misgivings about 
how to proceed with NIPS.  This indicates that practice guidelines would be useful to provide 
consistency, expert review of the costs and benefits, and a standard of care.  The careful 
consideration of revised prenatal screening routines is crucial to ensure patients receive the 
best possible care.
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